SOX2 and squamous cell carcinoma: Although SOX2 is a biomarker of interest in various squamous cell cancers and has been proposed as a valuable therapeutic target (15, 50), our study suggests that SOX2-directed therapies are unlikely to be effective in NC, especially as monotherapy.